Casirivimab, imdevimab and favipiravir, ATAGI guidance, Omicron sublineages

Peer reviewed journals featured:

- Randomised controlled trials of:
  - Casirivimab and imdevimab in COVID-19 patients admitted to hospital (RECOVERY) [here](#) and associated commentary [here](#)
  - Favipiravir in adults with mild COVID-19 [here](#)

- Observational studies on:
  - Effectiveness of mRNA vaccines and waning protection against SARS-CoV-2 infection and severe COVID-19 during the Delta variant outbreak in Italy [here](#)
  - COVID-19 risk following a ring vaccination intervention to address Alpha variant transmission in Montreal, Canada [here](#)
  - A data-driven testing program for the detection of COVID-19 cases [here](#)
  - Early prediction of COVID-19 pneumonia prognosis using age-adjusted Charlson Comorbidity Index, CRB score, and baseline oxygen saturation [here](#)
  - Herpes zoster related hospitalisation after inactivated (CoronaVac) and mRNA (Comirnaty) vaccination [here](#)
  - COVID-19 incidence and mortality rates associated with school reopening in Brazil [here](#)

- Commentary on mRNA vaccine development for infectious diseases [here](#)

Letters and correspondence discussed:

- Homologous and heterologous vaccine boosters in Singapore [here](#)

Pre-peer review articles featured:

- Long term antibody response to SARS-CoV-2 in children [here](#)
- SARS-CoV-2 neutralisation after mRNA vaccination and variant breakthrough infection [here](#)
- Antiviral activity of remdesivir and GS-441524 against Delta, Omicron, and other variants [here](#)
- Rapid antigen self-tests compared to RT-PCR from 1015 asymptomatic volunteers [here](#)
- Omicron and sub-variants (BA.1, BA.2 and BA.3) spike infectivity and pathogenicity [here](#)
- Persistence of SARS-CoV-2 immunity, Omicron's footprints, and projections of epidemic resurgences in South Africa [here](#)
Guidance and reports

- The World Health Organization released its latest Bulletin with articles on COVID-19 responses [here](#).
- The Australian Technical Advisory Group Immunisation (ATAGI) published guidance on:
  - Definitions of ‘up-to-date’ status for COVID-19 vaccination [here](#).
  - Comirnaty (Pfizer) vaccine as a booster dose in adolescents aged 16-17 years [here](#).
  - The use of Novavax COVID-19 vaccine (Nuvaxovid) [here](#).
- The UK Health Security Agency published updates of its COVID-19 vaccine surveillance report [here](#) and SARS-CoV-2 variants of concern and variants under investigation [here](#).
- The BMJ updated its best practice guide on COVID-19 [here](#).

News and blogs

- What we know about Omicron sublineages [here](#).
- Pandemic has harmed cancer outcomes and widened inequalities in the US [here](#).
- A podcast about African scientists copying the Spikevax (Moderna) vaccine [here](#).
- WHO prequalifies tocilizumab to treat COVID-19 [here](#).

Click [here](#) to subscribe to the daily evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on COVID-19 transmission, SARS-CoV-2 vaccines, and variants of concern, post-acute sequelae of COVID-19 (PASC), surgery and COVID-19, rapid testing and risk mitigation strategies.

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.